EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie

View source ↗

Summary

Cenrifki (tolebrutinib) has been authorised by the EMA for therapeutic use in multiple sclerosis, including chronic progressive forms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Cenrifki (tolebrutinib)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Chronic Progressive. MAH: Sanofi Winthrop Industrie. Decision date: 21/08/2026